CRSP Kronos AI forecast
A 30-trading-day price forecast for CRISPR Therapeutics AG Common Shares (CRSP) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts CRISPR Therapeutics AG Common Shares at $49.91 on 2026-12-08, −3.0% from the last close of $51.47 on 2026-10-27. Eight out of ten sampled paths end between $48.82 and $52.26, and 3 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of CRSP
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $50.99 | $49.81 | $51.59 |
| 2026-11-10 | $50.35 | $49.40 | $53.15 |
| 2026-11-17 | $50.93 | $49.07 | $54.40 |
| 2026-11-24 | $51.25 | $49.51 | $52.74 |
| 2026-12-01 | $50.62 | $49.25 | $53.63 |
| 2026-12-08 | $49.91 | $48.82 | $52.26 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for CRSP?
- Kronos AI's median forecast for CRSP is $49.91 in 30 trading days, −3.0% from the last close, with a 10–90% range of $48.82 to $52.26.
- Is the CRSP Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- AMGN — Amgen Inc.
- GILD — Gilead Sciences Inc.
- MRNA — Moderna Inc.
- ARGX — argenx SE American Depositary Shares
- RVMD — Revolution Medicines Inc.
- BIIB — Biogen Inc.